Kalaris reports positive Phase 1a data for TH103 in neovascular AMD study
KLRS•Pharmacokinetics and next trial stage
Plasma pharmacokinetics showed 27- to 53-fold lower Cmax versus leading anti-VEGF agents on a molar-equivalent basis, implying higher intraocular retention.
The Phase 1b/2 multiple-ascending-dose trial remains enrolling, and initial data are expected in 1H 2027 to guide Phase 3 dose selection.
Phase 1a data support longer durability
Kalaris reported positive expanded Phase 1a single-ascending-dose data for TH103 in neovascular AMD, supporting potential longer treatment durability.
The expanded dataset included 17 treatment-naive patients; 41% needed first retreatment at 4 months or later, and 29% needed none through 6 months.
